Remove Drug Pricing Remove Insurance Coverage and Processing Remove Presentation
article thumbnail

STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more

STAT

The evidence presented itself early this morning as the official mascots dashed about the grounds to bark about passersby, and a steady parade of driving machines could be seen from our window. ” While out-of-pocket caps on insulin indeed cut down on costs for commercially insured patients in the U.S.,

article thumbnail

NHC Comments on Negotiation Data Elements and Drug Price Negotiation Process for Initial Price Applicability Year 2027 under Sections 11001 and 11002 of the IRA ICR Forms

Putting Patients First Blog

The NHC appreciates CMS’ efforts to gather patient-centered data as part of this ICR and its commitment to making the process more relevant for patients and patient organizations. While we acknowledge these improvements, it is important to note that some aspects of the data collection process may remain challenging.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

First Drugs Selected for Price Negotiations Under The Inflation Reduction Act To Be Announced Next Week: A Recap of What That Means – The Drug Price Negotiation Program and Pending Legal Challenges

Big Molecule Watch

The Inflation Reduction Act’s Medicare Drug Price Negotiation Program will kick off next week. There are reports that the White House may announce the list of selected drugs even before that deadline, on Tuesday, August 29 th. Before the IRA, the government could not set prices for any drugs covered by Medicare.

article thumbnail

How early planning leads to successful market access and drug launch in Europe

Pharmaceutical Technology

Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. In Europe, the pricing and reimbursement (P&R) of pharmaceuticals is governed by individual member states.

article thumbnail

Drug Manufacturers’ 340B Restrictions Generate New Round Of Media Scrutiny & Criticism

Proxsys Rx

In the column, Hassell calls-attention to an earlier op-ed column published by The Hill as “yet another example of a drug company-focused view on the 340B Drug Pricing Program, couched in the language of reform.” “Its First, start with presenting drug company-funded research as if it is non-biased.